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I. Summary 
    Sapovirus (SaV) is known to cause acute gastroenteritis in human. It was first 
documented as a causative agent of acute diarrhea in an outbreak in an infant home in 
Sapporo, Japan in 1977. Later, SaV gastroenteritis has been reported in all age groups, 
but mainly in children less than 5 years old. The symptoms caused by SaV include 
vomiting, watery diarrhea, nausea, stomach pain and fever. 
     SaV belongs to the species Sapporo virus, genus sapovirus, in the family 
caliciviridae, which also include norovirus. SaVs are genetically and antigenetically 
highly diverse. Based on the entire capsid VP1 region sequence, human SaV can be 
divided into four genogroups (GI, GII, GIV, and GV) and further subdivided into 17 
genotypes. The emerging genotypes including novel genotypes and recombinant SaV 
have been reported to spread at the global level. With the application of molecular 
diagnosis technique, SaV has been recently recognized as the second or third major 
cause of viral gastroenteritis. However, the epidemiology of SaV has been poorly 
understood in developing countries, where acute diarrhea in children remains a major 
public health issue, mainly due to lack of expensive molecular methods for diagnosis. 
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Also, SaV gastroenteritis has been often reported in outpatient settings and outbreaks 
while the etiological role of SaV in severe hospitalized cases and transmission pattern in 
the community remain to be clarified. To better understand the prevalence and genetic 
diversity of SaV in severe gastroenteirtis and the epidemiology of SaV in the 
community in developing countries, here I conducted two studies: 1) Molecular 
detection and characterization of SaV in hospitalized children with acute gastroenteritis 
in the Philippines; 2) The prevalence and genetic diversity of SaV in a nested 
case-control study of a peri-urban community in Peru. 
    From June 2012 to August 2013, stool samples were collected from hospitalized 
children less than five years old due to acute gastroenteritis in three hospitals in 
different locations in the Philippines. SaV were detected in 7% of stool samples 
(29/417) by using real-time polymerase chain reaction (PCR). In 10 out of 29 
SaV-positive cases, other viruses were also detected, including rotavirus (n=6), 
norovirus (n=2), or human astrovirus (n = 2). I identified four known genotypes of SaV 
(GI.1 [7], GI.2 [2], GII.1 [12], and GV [2]) and a novel recombinant (n = 3) through 
sequencing analysis of polymerase and capsid gene. Full genome sequencing revealed 
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that the novel recombinant was closely related with GII.1 Bristol/98/UK variant at the 5’ 
nontranslated region (NTR) and nonstructural protein genes, whereas structural protein 
genes and 3’ NTR were closely related with the GII.4 Kumamoto6/Mar2003/JPN 
variant. This is the first study investigating SaV infection in the Philippines and the 
detection rate of SaV was not low in hospitalized children with acute gastroenteritis 
during the study period in three different islands. The novel, naturally occurring 
recombinant, SaV GII.1/GII.4 detected from two distant islands indicated its spread in 
different regions in the Philippines. To define the significance of the novel recombinant 
strain, continuous monitoring is required. 
    SaV is frequently detected together with other gastroenteric viruses in symptomatic 
cases as shown in study 1 and is also detected from healthy individuals. Therefore the 
causative roles of SaV in acute gastroenteritis remain to be clarified. A birth cohort 
study of childhood diarrhea was conducted between June 2007 and May 2010 in a 
peri-urban community in Lima of Peru. To better understand pathogenicity and clinical 
symptoms caused by SaV, I conducted a case-control study of SaV by analyzing the 
stored diarrheal and non-diarrheal stool samples from this birth cohort study. I 
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randomly selected 300 diarrheal stools and 300 non-diarrheal stools to test SaV. SaV 
was found in 12.3% of diarrheal and 5.7% of non-diarrheal stool samples using 
real-time PCR. I found that the attributable fraction (AF) of SaV was higher in the 
second year (13.1%) than the first year of life in children (1.4%). Ten known genotypes 
(GI.1[9], GI.2[2], GI.6[3], GI.7[7], GII.1[2], GII.2[4], GII.4[4], GII.5[1], GIV[2], and 
GV.1[5]) and one novel genotype in GII (n=5) were found. Symptomatic reinfection 
causing by different genogroups (n=5) and genotypes (n=3) were observed in eight 
children and it suggest SaV may develop genotype specific immunity. This study 
indicates SaV leads to community acquired diarrhea, especially in the second year of 
live of infants in developing area. Multiple genotypes circulating in one community and 
possible genotype specific immune response could complicate the SaV vaccine 
development. 
    My studies showed that SaV was prevalent both in hospital and community 
settings in developing countries. The detection rate of SaV in diarrheal stools was 
significantly higher than in non-diarrheal stools. Although, the involvement of SaV in 
acute gastroenteritis is lower compared to rotavirus and norovirus, its importance in 
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acute gastroenteritis particularly in severe cases needs to be further clarified in a large- 
scale study. Also, novel genotypes of SaV detected in both studies suggested that 
long-term, large-scale surveillance should be conducted to define genetic diversity and 
clinical and public health significance of SaV. Notably, symptomatic reinfection 
observed in this study provided new insight to protective immunity of SaV infection.  
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II. Introduction 
    Sapovirus (SaV) is known to cause acute gastroenteritis in humans. The SaV 
particle was discovered in human diarrheal stools in 1976 in the United Kingdom using 
electron microscopy (EM) (1). Later, it was documented as a causative agent of diarrhea 
in an outbreak in an infant home in Sapporo, Japan in 1977 (2). Soon, this virus has 
been recognized as a new pathogen of sporadic gastroenteritis and outbreaks in different 
settings, such as hospital (3), school (4), care facility (5) and cruise ship (6). SaV can 
cause gastroenteritis in all age groups, but mainly in children less than 5 years old (7, 8).  
    SaV was previously named “Typical human caliciviruses” or “Sapporo-like 
viruses”. It was assigned to the species Sapporo virus, genus sapovirus, in the family 
caliciviridae, which also include norovirus (9). The virions are nonenveloped and 
approximately 27 to 40 nm in diameter. The icosahedral capsid surrounds a 
positive-sense single-stranded RNA genome covalently linked to VPg at the 5′ end, 
polyadenylated at the 3′ end, and approximately 7.7 kb in length (10) (Figure 1). The 
RNA genome is organized into two or three open reading frames (ORFs) and ORF1 
encodes a large polyprotein containing the nonstructural proteins (NS, NS1-NS7) 
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followed by a major capsid protein, VP1 (11) (Figure 2). ORF2 and ORF3 encode 
proteins whose functions are still unknown. The capsid protein is thought to be cleaved 
from the ORF1 polyprotein by protease and/or directly translated from subgenomic 
RNA (12, 13). SaV can infect both human and animals, but interspecies transmission is 
rarely documented (13). SaVs are genetically and antigenically highly diverse. Based on 
the entire VP1 region sequence, human SaV can be divided into four genogroups (GI, 
GII, GIV, and GV) and further subdivided into 17 genotypes (GI.1–7, GII.1–7, GIV.1, 
GV.1–2) with cut off value ≤0.488 and ≤ 0.169 pairwise distance, respectively (11, 14).  
    Recombination, which is defined as the exchange of genetic information between 
nonsegmented RNAs, is an important evolutionary force for RNA viruses. The most 
widely accepted model of recombination for RNA viruses is the ‘copy choice’ 
recombination (15). In this process, the RNA polymerase that mediates viral replication 
switches from one RNA molecule (the donor template) to another (the acceptor 
template) during synthesis while remaining bound to the nascent nucleic acid chain, 
thereby generating an RNA molecule with mixed ancestry (16). Various factors 
influence template switching, including the extent of local sequence identity between 
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the RNA templates, the kinetics of transcription and secondary structure in the RNA 
(17).  Several studies have reported that recombination typically occurs at the junction 
of polymerase and capsid genes within ORF1 of SaV, which may generate antigenically 
distinct strain (18, 19). Some recombinant SaV has caused outbreaks in various 
countries (5, 20, 21). 
    Compared to rotavirus and norovirus, other two major causes of viral acute 
gastroenteritis, SaV generally cause a relatively mild or moderate gastroenteritis with 
the median duration of 2–5 days of illness (5, 7, 22).  However, SaV associated severe 
cases also have been documented (23). Common symptoms include nausea, vomiting, 
watery diarrhea, stomach cramps, and fever. All those symptoms are indistinguishable 
from those caused by other viral gastroenteric pathogens, therefore laboratory diagnosis 
is essential to diagnose SaV infection. Human SaV still cannot be cultured in vitro, 
reverse transcription polymerase chain reaction (RT-PCR), especially real-time PCR, 
which targeted on the RNA-dependent RNA polymerase (RdRp) (24), VP1 (25) or 
junction of RdRp-VP1 (26) has been widely used to detect the virus from stool samples. 
The virus shedding in both children and adults generally stops after two weeks since 
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onset of symptom, which is shorter than norovirus (7, 27-29). The detection rates of 
SaV in diarrhea varied in different geography and settings and are likely to be affected 
by the diagnosis techniques used (8). In Japan, the detection rates of in outbreaks and 
sporadic case of acute gastroenteritis were 8% (30) and 4.0–6.6% (31-33), respectively. 
With the application of sensitive PCR, SaV was recently defined as the second major 
viral cause of acute gastroenteritis after norovirus in a large-scale population-based 
study in all age groups in UK in 2008–2009 (8), and the detection rates of SaV have 
increased up to 8.8%–17% in several countries (34, 35). Since outbreak reports of SaV 
in all age groups have been increased worldwide recently, SaV diagnostic assay is 
recommended to be conducted during viral gastroenteritis outbreaks (36). Notably, SaV 
together with norovirus may become the major causative agents of viral acute 
gastroenteritis among children in countries that implement national rotavirus 
vaccination, as indicated in Nicaragua (35). However, the epidemiology of SaV has 
been poorly understood in developing countries, where acute diarrhea in children 
remains a major public health issue, mainly due to lack of expensive molecular methods 
for diagnosis. Also, SaV gastroenteritis has been often reported in outpatients (32, 34, 
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37-39) and outbreak settings (4-6, 30, 36) while the epidemiology of SaV in severe 
hospitalized cases (40) and community settings (7, 41) remains to be clarified. Here, the 
present studies were conducted in order to: 1) detect SaV in hospitalized children with 
acute gastroenteritis in the Philippines; 2) compare the prevalence of SaV in diarrhea 
and non-diarrhea stool samples in a peri-urban community in Peru; 3) characterize the 
genetic diversity of SaV in the Philippines and Peru. 
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III. Study 1: Molecular detection and characterization of SaV in hospitalized 
children with acute gastroenteritis in the Philippines 
1. Background 
    Compared to rotavirus and norovirus, SaV is generally believed to cause milder 
gastroenteritis (5, 7, 22). But some evidences showed that SaV associated gastroenteritis 
can be severe (42). The detection rates of SaV in hospitalized gastroenteritis cases were 
≤5% in previous studies conducted in Japan (22), USA (43), Australia (40), Thailand 
(44), India (45), Denmark (34), Italy (46), and Vietnam (47). However, with rotavirus 
vaccine introduction, the relative importance of SaV in severe gastroenteritis may be 
increasing as shown in a recent study conducted in Nicaragua, where SaV were found in 
15% of vaccinated children hospitalized for acute diarrhea (35). Despite a potential 
etiological importance of SaV, SaV infection has not been conducted in the Philippines. 
2. The objective 
    To define the prevalence and genetic characteristics of SaV among hospitalized 
children with acute gastroenteritis in the Philippines. 
3. Study designs 
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3.1 Study sites and sample collection 
    We conducted a prospective etiological study in hospitalized children aged less 
than 5 years due to acute gastroenteritis between June 2012 and August 2013 in three 
hospitals (Figure 3): Eastern Visayas Regional Medical Center (EVRMC), Tacloban 
City in Leyte Island; Ospital ng Palawan (ONP), Puerto Princesa City in Palawan 
Island; and Philippine Children's Medical Center (PCMC), Metro Manila.  Children 
with acute gastroenteritis who stayed at hospitals for a minimum of 24 hours were 
regarded as hospitalized cases. Informed consent was obtained from parents or legal 
guardians of children before stool sampling. Age (date of birth), gender, and history of 
vaccination for rotavirus of participants were recorded. Stool specimens were collected 
within 72 hours after onset of illness and transported at 4°C to the Research Institute for 
Tropical Medicine (RITM) in Metro Manila and stored at −80°C until processing. 
3.2 Detection of gastroenteric viruses using reverse transcription PCR or real-time 
PCR  
    Viral nucleic acid was extracted from 20% clarified stool suspension prepared in 
phosphate-buffered saline (PBS) using QIAamp MinElute Virus Spin Kit (Qiagen, 
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Hilden, Germany). For denaturation of double-stranded RNA to detect rotavirus, 0.5 µl 
(0.3 mg/ml) of random primers (Life Technologies, Carlsbad, CA, USA), 0.5 µl of 
deoxynucleotide triphosphates (10 mM, Life Technologies), and 4.25 µl of the extracted 
viral RNA were heated at 98°C for 5 min, followed by cooling on ice for 2 min. In total, 
4.75 µl of the RT mixture, which contained 2 µl of 5× First-Strand buffer (Life 
Technologies), 0.5 µl of dithiothreitol (0.1 M, Life Technologies), 0.25 µl of 
RNaseOUT (40 U/µl, Life Technologies), 0.25 µl of SuperScript III reverse 
transcriptase (200 U/µl, Life Technologies), and 1.75 µl of RNase free water was added, 
and the mixture was incubated at 25°C for 5 min, then at 50°C for 60 min, followed by 
inactivation of the enzyme at 70°C for 15 min.  
    SaV and human astrovirus were screened by duplex real-time PCR by using 
previously described primers and TaqMan probes (26, 48). The duplex real-time PCR 
was performed using an ABI 7500 Fast Real-Time PCR system with TaqMan Fast 
Advanced master mix (Life Technologies). The detection limit was determined by 
standard curves generated with 10-fold serial dilutions (107 to 10) of SaV GII.1 standard 
plasmid, and 100 copies/µl of cDNA corresponded to the cycle threshold (Ct) value of 
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38. Therefore, a sample with a Ct value <38 was considered to be a positive for SaV. 
Three Positive and one negative controls were included to confirm its expected Ct 
values. Norovirus group II was tested with primer pairs of COG2F (49) and G2SKR 
(50) by conventional PCR. Rotavirus was tested by the G and P genotyping methods 
using conventional PCR system (51). 
3.3 SaV genotyping and nucleotide sequencing  
    SaV-positive samples were genotyped by nested PCR targeting the partial capsid 
region (25) and conventional PCR target polymerase region, respectively. For samples 
in which different genotypes of SaV were identified for capsid and polymerase regions, 
a long gene segment covering the consecutive capsid and polymerase regions was 
amplified by region specific primer pairs (Table 1) to check the possibility of 
coinfection with different SaV strains. Long PCR products were TA cloned into 
pGEM-T easy vector (Promega, Madison, Wisconsin, USA). To find other possible 
recombination points, additional primers were designed, and four overlapping segments 
were amplified to cover the full genome of one of the recombinant strains (Figure 4). 
All PCR products were purified by QIAquick PCR purification kit (Qiagen), sequenced 
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using BigDye Terminator version 1.1 (Life Technologies), and analyzed using Applied 
Biosystems 3700 Genetic Analyzer (Life Technologies). Primers for SaV, used in this 
study, are summarized in Table 1. The SaV sequences obtained in this study were 
deposited in GenBank under accession numbers KP067397-KP067418 for the 
polymerase sequences, KP067419-KP067443 for the capsid sequences, and KP067444 
for the full genome sequence. 
3.4 Sequence analysis and Recombination analysis 
 The sequence data were aligned by clustalW and phylogenetic trees were 
constructed by the neighbor-joining method with Kimura 2 parameter settings using 
MEGA 5 software package (52). The closest sequence available in GenBank and the 
sequence similarity between analyzed samples and reference sequences were identified 
using the Basic Local Alignment Search Tool (http://blast.ncbi.nlm.nih.gov/Blast.cgi). 
Possible events and the confidence value of recombination between suspected 
recombinant and parent strains were examined by RDP4 (53). The genetic similarity 
between recombinant and putative parent strains were plotted by SimPlot (54). 
3.5 Statistical Analysis 
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    All the statistical analysis was performed by Mann-Whitney U test using Stata 
software, version 12 (StataCorp, College Station, Texas). 
4. Ethical approval 
    This study was approved by the Ethics Committee of Tohoku University Graduate 
School of Medicine, Sendai, Japan, and the Institutional Review Board (IRB) of 
Research Institute for Tropical Medicine, the Philippines. 
5. Results 
5.1 Prevalence of SaV 
 A total of 417 stool samples (from 166 males and 251 females) were tested for SaV, 
astrovirus, rotavirus, and norovirus genogroup II. The overall detection rate of SaV 
was 7.0% (29/417): 7.0% in EVRMC (18/257), 7.8% in ONP (8/103), and 5.3% in 
PCMC (3/57). The age distribution of tested cases and SaV-positive cases was shown 
in Figure 5. The median and mean age of the tested cases were 12.0 (interquartile 
range, 7.5–19.0 months) and 14.7 months, respectively. The highest proportion of 
SaV-positive samples was observed in children aged 18–23 months. There was no 
significant difference in detection rate between male and female (6.4% vs 7.8%, p = 
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0.56). For other three viruses, rotavirus was the most common virus identified (50.6%, 
211/417), followed by norovirus genogroup II (6.0%, 25/417), and astrovirus (4.1%, 
17/417). Among 29 SaV-positive cases, 10 cases were also positive for other viral 
pathogens including rotavirus (n = 6), norovirus (n = 2), and astrovirus (n = 2). The 
median viral load of SaV was lower in only SaV-positive cases than in those with 
co-infection, although it was not statistically significant (218047 vs 1805 copies 
cDNA/µl, [interquartile range, 1799–412463 vs 1461–11763 copies cDNA/µl], p = 
0.55). Demographic information, history of vaccination of rotavirus, viral load, 
genotypes and infection of virus of each case are shown in Table 2. 
5.2 Molecular characterization of SaV and phylogenic analysis 
The partial capsid gene sequence (364-nucleotides [nt]) was determined for 26 of 
the 29 SaV-positive samples because three samples were not sequenced due to 
suboptimal amplification by PCR. Five different genotypes were identified: GI.1 (7), 
GI.2 (2), GII.1 (12), GII.4 (3), and GV (2). Of the 12 SaV GII.1 strains, 11 were 
clustered with the GII.1 Bristol/98/UK strain in the phylogenetic tree (Figure 6a) and 
showed 96–98% nt homology to this prototype strain. All GI.1 strains from this study 
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showed 99% nt homology to the Manchester strain (X86560). Three GII.4 strains 
shared the highest similarity (91–92%) with the GII.4 Kumamoto6/Mar2003/JPN strain 
(AB429084). Two GI.2 strains were observed in the late phase of the study period (July 
2013), and shared 99% nt homology with the emerging GI.2 strains. 
A second phylogenetic tree was constructed based on the partial polymerase gene 
(463 nt; Figure 6b). All strains, except for three GII.4 strains, were clustered into the 
concordant genotypes assigned by the capsid gene sequences. In contrast, all three GII.4 
strains, which shared 99% nt homology, were clustered into SaV GII.1 and were distant 
from the GII.4 Kumamoto6/Mar2003/JPN strain. Thus, these three strains were 
suspected to be GII.1/GII.4 recombinants. Two of these three strains were detected at 
EVRMC on Leyte Island in July and August 2012 and one was detected from a patient 
at ONP on Palawan Island in September 2012. In one of these three cases, rotavirus was 
also detected. 
5.3 Recombination analysis 
Since the partial polymerase and capsid sequences of the three suspected 
recombinant samples shared 99% similarity, I selected two samples: TGO12-028 from 
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ONP on Palawan Island and TGE12-030 from EVRMC on Leyte Island to rule out the 
possibility that detection of different genotypes in the polymerase and capsid regions 
was due to mixed-infection with different SaV strains. Sequencing of multiple clones 
carrying the partial polymerase and capsid (954 nt) regions showed that only GII.1 and 
G.II4 sequences were detected in polymerase and capsid gene clones, respectively. The 
full genome of SaV from TGO12-028 was further characterized [7,460 nt, excluding the 
poly (A) tail of ORF1 (14–6,853 nt) and ORF2 (6,853–7,353 nt)]. TGO12-028 shared 
the highest similarity (94% at the nt level and 99% at the amino acid level) with GII.1 
Bristol/98/UK in the nonstructural protein region (14–5,173 nt). However, in the 
structural protein region (5,174–7,353 nt) the similarity between them was only 74% at 
the nt level and 83% at the amino acid level. In contrast, TGO12-028 showed the 
highest similarity (92% at the nt level and 99% at the amino acid level) to GII.4 
Kumamoto6/Mar2003/JPN in the structural protein region, and lower nucleotide 
similarity (85%) in the partial polymerase region (4,523–5,173 nt). These results 
indicate that TGO12-028 is a recombinant virus containing a portion of a 
Bristol/98/UK-like virus and a Kumamoto6/Mar2003/JPN-like virus. A recombination 
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point for TGO12-028 was identified at position 5,166 (p = 7.44 × 10−29) by RDP4. 
Since the longest SaV GII.4 sequence available in GenBank is 
Kumamoto6/Mar2003/JPN (total length, 2,982 nt; covering the 3ʹ end of the polymerase, 
the entire structural protein region, and the 3ʹ NTR), TGO12-028 was plotted against the 
full genome sequence of GII.1 Bristol/98/UK and the 3ʹ terminus of GII.4 
Kumamoto6/Mar2003/JPN (4523–7460 nt, Figure 7). 
6. Discussion 
   In this study, I detected SaV in the Philippines for the first time and the detection 
rate of SaV was relatively high in hospitalized gastroenteritis in this study. The overall 
SaV-positive rate (7.0%) was higher than those in similar studies (0–5%) of 
hospitalized children with gastroenteritis in Thailand (44), Japan, Denmark (34), USA 
(43), and Australia (40). The higher detection rate of sapovirus in this study was not 
because of rotavirus vaccination since only two patients (2/419, 0.5%) in this study had 
received rotavirus vaccines. A possible explanation for the higher SaV detection rate in 
this study could be the use of real-time PCR targeting the conserved region at the 
junction between polymerase and capsid genes, which can amplify multiple genogroups 
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of SaV (26). Other studies used single round PCR (34, 40, 43), which targeted relatively 
diverse regions of polymerase or capsid and failed to amplify several variant genotypes. 
A study showed that real-time PCR with similar primers and probes as I used in this 
study had 10-fold higher sensitivity than the single round PCR (55). Humans are the 
only natural host for human SaV, which can be transmitted either by direct 
person-to-person contact or through contaminated food or water. In addition, the higher 
prevalence of SaV in this study could be due to the poor sanitary condition in the 
Philippines, compared to developed countries where most other studies were conducted. 
Although I found that approximately 30% of SaV-positive cases were also positive for 
other gastroenteric viruses, the median viral load of SaV was much higher in only 
SaV-positive cases than in those with co-infection. However, in this study, I could not 
compare the severity or clinical manifestations between SaV-positive only and 
co-infection cases since detailed information on clinical symptoms was not recorded.  
 In the study period (2012–2013), SaV GII.1 was most commonly detected, 
whereas GI.2 was a dominant genotype during the same period in neighboring countries, 
including Japan and China (37). SaV GII.1 has been a common genotype worldwide but 
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not dominant in most studies (33, 34, 56). A majority GII.1 strains found in this study 
are close to the prototype strain GII.1, Bristol/98/UK. The second most common 
genotype was GI.1 closely related to Manchester/X86560 strain.  
    To date, three types of SaV recombinants have been described: inter-genogroup 
(e.g., GII/GIV) (18), inter-genotype (e.g., GI.1/GI.2 and GII.2/GII.3)(57), and 
intra-genotype (e.g.,GI.1b/GI.1a) (58) recombinant strains. Among these recombinant 
strains, GII/GIV has caused several outbreaks in Japan, USA, and Canada between 2006 
and 2009 and it continues causing sporadic cases in several other countries (5, 20, 21). 
In this study, I identified another novel inter-genotype recombinant GII.1/GII.4 in three 
cases from two distant islands between July and September in 2012. This indicated that 
the recombinant GII.1/GII.4 had been circulating for a certain period and spread to 
different areas of the Philippines. The putative recombination breakpoint was located at 
the junction of polymerase and capsid genes, where the majority of recombinant points 
have been identified for both SaV and norovirus (59). The junction of polymerase and 
capsid genes on the antisense strand of calicivirus was predicted to have conserved 
subgenomic RNA promoters and stem-loop structures, which could facilitate the 
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exchange of templates during virus replication (59, 60). GII.1 strains have been 
commonly detected in other countries as well as in this study while GII.4 strains was 
only detected in Pakistan (1992), Japan (2003 and 2008), Vietnam (2006), UK (2008), 
Brazil (2010), and Kenya (2014) by reviewing sequence databases. The GII.1/GII.4 
recombinant may have emerged as a result of a commonly circulating GII.1 strain 
capturing the capsid of the uncommon GII.4 strain within a host who was 
simultaneously infected with both strains. I assumed that multiple synonymous 
substitutions occurred at this novel recombinant after recombination because there was 
only about 92% or 94% nucleotide similarity but 99% amino acid similarity between 
the recombinant and donor segments of the circulating tentative parent strains (GII.1 or 
GII.4). By acquiring a new capsid gene, inter-genotype recombinants display different 
antigenicities (61), therefore, they could escape from herd immunity and cause 
outbreaks, as suggested by SaV GII/GIV and GII.2/GII.3 (20). SaV GII.1/GII.4 
recombinant strains were detected in two distant islands in the Philippines, i.e. Leyte 
and Palawan Islands, which suggest that these recombinant strains were widely 
circulating in the Philippines. Therefore, continuous monitoring is required to reveal the 
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significance of this reveal the significance of this novel recombinant.  
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IV. Study 2: The prevalence and genetic diversity of sapovirus in a nested 
case-control study in a peri-urban community in Peru 
1. Background 
SaV associated severe gastroenteritis and outbreaks have been reported, which 
indicated its importance. However, SaV was frequently detected with other enteric 
pathogens in symptomatic cases as shown in study 1 and in healthy individuals. 
Therefore etiological role of SaV in acute diarrhea remains to be clarified. Also, in 
study 1, the clinical information of hospitalized children was not available. A birth 
cohort study of acute diarrhea in children less than two years old was conducted 
between June 2007 and May 2010 in a peri-urban community of Lima, Peru (29). Field 
workers visited the participated family to record the symptoms of acute diarrhea and 
collect stool specimens twice weekly. To better understand pathogenicity and clinical 
symptoms caused by SaV, I conducted a case-control study of SaV by analyzing the 
stored diarrheal and non-diarrheal stool samples from the birth cohort study in Peru.  
    Two very early population based case-control studies conducted 15 years ago in 
England (62) and the Netherlands (63) reported that SaV primary infects children less 
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than 5 years old, with the detection rate of 6.8–13.0% in symptomatic and 1.8–3.0% in 
asymptomatic children. One surveillance in USA recently reported that SaV was found 
in 5.4% in symptomatic and 4.2% in asymptomatic children less than five years old (39). 
However, data measuring the impact of SaV at the community levels in developing 
countries (41) are sparse.  
2. Objectives 
    To compare the prevalence of SaV in diarrhea and non-diarrhea stool samples and 
characterize the genetic diversity of SaV in a peri-urban community in Peru  
3. Study design 
3.1 Stool sample selection 
    Totally 291 children were enrolled and 189 children were followed up to 2 years 
old in the birth cohort study. Enrolled families were visited twice weekly and stool 
samples regardless of presence of diarrhea or not were collected weekly by field 
workers. Diarrhea was defined by the presence of ≥3 liquid or semiliquid stools in 24 
hours. For infants younger than 2 months, the definition was based on the mother's or 
caretaker's assessment if the child had diarrhea (64). A diarrhea episode was considered 
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to have ended when the child had 2 consecutive days without diarrhea. I assumed SaV 
could be detected at least 5% of children with acute diarrhea based on the detection 
rates in other four main population based studies (5.4–16.6%) in UK, the Netherlands, 
USA and Nicaragua (39, 41, 62, 63). Then I decided to test 20-40 samples for each age 
group to make sure that at least 1–2 positive stool samples in diarrhea stools could be 
detected in each age group. Since a total number of diarrhea episodes in each age group 
was ranging from74 to126 in this cohort study (Table 3), I decided to test about one 
third of total episodes (25–42). Finally, 300 diarrheal stools and 300 non-diarrheal 
stools were selected from stored stool samples to test SaV in this study. Three hundred 
episodes were randomly selected based on age and seasons from a total 862 episodes 
with diarrheal stools. The first stool was selected if more than one stools in the episode. 
The age groups and collection date of stools were divided by three months and four 
seasons (Dec-Feb, Mar-Jun, Jul-Sep and Oct-Jan), respectively. The sample size in each 
age group ranged from 26 to 44. Age (same group) and season matched non-diarrheal 
stool was randomly selected from weekly stool samples. Also, the non-diarrheal stools 
were defined as stools which were not collected within the diarrhea episode period, 
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within one week before the first day of diarrhea episodes or within two weeks after the 
last day of diarrhea episodes based on SaV incubation periods (1–4 days) (11) and 
shedding duration of about two weeks (7, 28). 
3.2 Reverse Transcription (RT) and real-time polymerase chain reaction for SaV 
    Viral nucleic acid was extracted from 10% clarified stool suspension prepared in 
phosphate-buffered saline (PBS) using QIAamp viral RNA kits (Qiagen, Hilden, 
Germany) according to manufacturer’s instruction. cDNA were synthesized by M-MLV 
reverse transcriptase kits with random primers. Briefly, 0.5 µl (0.3 mg/ml) of random 
primers (Life Technologies, Carlsbad, CA, USA), 0.5 µl of deoxynucleotide 
triphosphates (10 mM, Life Technologies), and 5.5 µl of the extracted viral RNA were 
heated at 65°C for 5 min, followed by cooling on ice for 2 min. In total, 3.5 µl of the RT 
mixture, which contained 2 µl of 5× First-Strand buffer (Life Technologies), 1 µl of 
dithiothreitol (0.1 M; Life Technologies), 0.25 µl of RNaseOUT (40 U/µl, Life 
Technologies) and 0.25 µl of M-MLV reverse transcriptase (200 U/µl, Life 
Technologies) was added, and the mixture was incubated at 25°C for 5 min, then at 
37°C for 60 min, followed by inactivation of the enzyme at 70°C for 15 min. Real-time 
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PCR targeting RdRp-VP1 junction of SaV was performed on an ABI 7500 Fast 
Real-Time PCR system (Life Technologies), using published primers and probes(26). 
The detection limit was determined by standard curves generated with 10-fold serial 
dilutions (107 to 10) of SaV GII.1 standard plasmid, and 100 copies/µl of cDNA 
corresponded to the cycle threshold (Ct) value of 38. Therefore, a sample with a Ct 
value <38 was considered to be a positive for SaV. Three Positive and one negative 
controls were included to confirm its expected Ct values. 
3.3 Genotyping and sequence analysis 
    SaV-positive samples were amplified by hemi-nested PCR targeting on the partial 
capsid region with first round primer pairs SV F13/F14 (25) and SaV5857R-1/-2 and 
second round primer pairs SaVF1245 and SaV5857R-1/-2. Cycling conditions for 
hemi-nested PCR were 94°C for 5 min, then 35 cycles of 94°C for 30 sec, 50°C for 30 
sec and 72°C for 1min, followed by 1 cycle of 72°C for 10 min. For the new genotype 
of SaV, the full capsid gene was amplified with primer pair SV F13/F14 (25) and 
SaVGIIR under following cycling conditions: 94°C for 5 min, then 35 cycles of 94°C 
for 30 sec, 54°C for 30 sec and 72°C for 2 min, followed by 1 cycle of 72°C for 10 min. 
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All PCR products were purified by QIAquick PCR purification kit (Qiagen), sequenced 
using BigDye Terminator version 1.1 (Life Technologies) with Primer SaV F1245, 
which modified from SaV R1245 (26), and analyzed using Applied Biosystems 3700 
Genetic Analyzer (Life Technologies). Primers for SaV, used in this study, are 
summarized in Table 4. The sequence data were aligned by clustalW and phylogenetic 
trees were constructed by the neighbor-joining method with Kimura 2 parameter 
settings using MEGA 5 software package (52). The closest sequences available in 
GenBank and the sequence similarity between analyzed samples and reference 
sequences were identified using the Basic Local Alignment Search Tool 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi). 
3.4 The formula of the population attributable fraction (AF) of diarrhea due to 
SaV  
    The AF of a disease due to a risk factor is the proportion of disease cases (or the 
proportion of the risk of disease) that might theoretically be eliminated if the risk factor 
were eliminated. AF can be estimated equivalently from the distribution of the exposure 
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(risk factor) either in the entire population or in cases of disease. In study I use AF to 
estimate the fraction of diarrhea due to SaV and the formula of AF (65) is given by 
.  
Pr(SaV/diarrhea)is the proportion of SaV in diarrhea stools. OR is the odds ratio of SaV 
for diarrhea. 
3.5 Statistical Analysis 
    All the statistical analysis was performed by Mann-Whitney U test using Stata 
software, version 12 (StataCorp, College Station, Texas). 
4. Ethics statement 
    This study was approved by the Ethics Committee of Tohoku University Graduate 
School of Medicine, Sendai, Japan, and Asociación Benéfica PRISMA, Universidad 
Peruana Cayetano Heredia (UPCH), Johns Hopkins University, the Centers for Disease 
Control and Prevention (CDC), and the European Union. Each woman provided written 
informed consent for her infant. 
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5. Result 
    SaV were detected in 8.8 % of 600 stools from children aged less than 24 months, 
with 12.3% in diarrheal stools (37/300) and 5.7% in non-diarrheal stools (17/300) in 
this community. The symptoms of 37 SaV associated diarrhea episodes were shown in 
Table 5. The median duration of SaV associated episodes was 3 days (interquartile 
range, 3–5 days). The median maximum daily number of diarrheal stools was 4 
(interquartile range, 3.5–5.5). Fifteen episodes (40.5%) had vomiting and only four 
episodes had fever. The infection in children aged less than 2 years was varied between 
different age groups (Figure 8). For children aged less than 6 months, SaV was only 
detected in non-diarrheal stools. For children aged 6–23 months, the detection rates of 
SaV were 9.1–26.7% of diarrhea stools, which were higher than those of non-diarrheal 
stools (2.4–8.6%) in the same group. The SaV AF in diarrhea was 1.4% in the first year 
and 13.1% in the second year of life. SaV were detected together with norovirus only in 
three diarrheal stools. SaV was observed in every month of the year and. In the 
real-time PCR, the median viral load of SaV was higher in diarrheal samples than in 
non-diarrheal samples (412463 vs 21544 copies cDNA/µl, interquartile range 4467–
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2097949 vs 5741–440139 copies cDNA/µl, p = 0.024).  
    Of 54 real-time PCR positive specimens, 48 specimens were amplified by 
conventional PCR and had readable sequences. In total, 10 known genotypes (GI.1, 
GI.2, GI.6, GI.7, GII,1, GII.2 GII.4, GII.5, GIV, and GV.1) among four genogroups (GI, 
GII, GIV and GV)  were identified by phylogenetic analysis of 628 bp of capsid 
region(5227–5854nt corresponding of Manchester, X86560)(Figure 9). GI (n=22) and 
GII (n=16) constituted 70.4% of positive cases. The proportion of GI, GII, GIV and GV 
among diarrheal and non-diarrheal stools was 51.5% vs 33.3%, 27.3% vs 46.7%, 12.1% 
vs 0, 9% vs 20%, respectively. The median viral load of SaV GI, GII, GIV and GV in 
stools and non-diarrheal stools was 422319 vs 6422 copies cDNA/ul, 440139 vs 18920 
copies cDNA/µl, 19145 vs 0 copies cDNA/µl, 8576959 vs 440139 copies cDNA/µl, 
respectively. I did not find clear seasonality of SaV genotypes between diarrheal and 
non-diarrheal stools. From phylogenetic tree of partial capsid region, five strains from 
this study and one US strain fell into a possible novel cluster in GII. These five strains 
showed less than 78% similarity with other genotypes of GII. Two of them were found 
in diarrheal stools and the remaining three strains were found in non-diarrheal stools. 
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By sequencing the full capsid region of one of five strains, it formed a single cluster in 
the phylogenetic tree (Figure 10) and displayed 0.298–0.466 pairwise distance with 
other 7 genotypes of GII (GII.1–7). Therefore, these novel strains can present a new 
genotype. Demographic information, viral load, genotype, repeated infection of SaV 
positive stool samples are shown in Table 6.  
    Eight children experienced SaV infections twice (Table 6). Five of them had 
repeated infection with different genogroups, and the other three of them had repeated 
infection with different genotype within GI and GII. Seven children experienced two 
SaV associated diarrheal episodes and for one child the first SaV infection due to GII.1 
was asymptomatic and subsequently SaV GII.2 infection was symptomatic. For these 
double infections, none of them were detected with norovirus.  
6. Discussion 
    To my best knowledge, there has been no large-scale community-based study on 
SaV in South America. I found that SaV was commonly detected both in diarrhea and 
non-diarrheal stools in Peru. SaV contributed to acute gastroenteritis in children less 
than two years old, especially in the second year of life. Very few case control or cohort 
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studies have described SaV infections in both symptomatic and asymptomatic diarrhea. 
From population based cohort studies and surveillance, SaV were found in 5.4–16.6% 
of symptomatic cases and less than 4.2% of healthy control of children less than five 
years old in England(62), the Netherlands(63), USA(39) and Nicaragua(41). Our study 
(18.6% vs. 7.1%) together with the recent Nicaragua study (19.4% vs. 10.9%) indicated 
that higher SaV-positive rates were observed in children aged 12–23 months compared 
to children < 12 months old with diarrhea. Similarly, the USA population based 
surveillance reported SaV were detected more commonly in symptomatic children aged 
1–2 years, whereas the virus was more frequently detected in healthy children aged <1 
year. All these finding indicated that SaV may be more associated with acute 
gastroenteritis in the second year of life of children, which is similar to norovirus (29), 
and different to rotavirus (66). No SaV infection was found among diarrhea children 
aged less than 6 months and the detection rate was increasing with age in the diarrheal 
stools of children less than one year old in this study. SaV infection was less frequently 
observed among children aged less than 6 months in Denmark and Nicaragua (34, 35). 
The lowest proportion of SaV diarrhea in children less than 6 months old possibly 
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reflected the protective effect of breastfeeding and transferred maternal antibodies (29, 
67). However, SaV diarrhea were also observed mainly in children < 6 months old in 
the cohort study in the Netherlands, which suggested the absence of maternal antibody 
of SaV(7). The discrepancy may be explained by difference in maternal immunity levels 
against SaV in infants and sanitary condition in different geographical areas (68-70). In 
line with other reports(39, 71), I found as high as 5.7% SaV in asymptomatic children 
and those cases may be an important carrier of this pathogen(72). 
   This was the first cohort study describing the repeated infection of SaV. Five 
children were observed to have symptomatic re-infection with different genogroups, and 
the same observation was also reported in two patients in Japan (11). In addition, for the 
first time, I found three children experienced symptomatic reinfection with different 
genotypes. However, I did not test other enteric pathogens except norovirus, it could be 
possible that undetected other pathogens might contribute to symptoms. In the future, to 
better define the causative roles of SaV in acute gastroenteritis, the attributable fraction 
of SaV should be adjusted by the presence of other pathogens. A very little information 
is available about protective immunity to SaV infection. A very early study reported 
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that the presence of preexisted serum antibody of SaV in infants was associated with 
resistance to subsequent illness, at least for antigenically homologous SaV (73). Our 
observation suggested that the primary infection with SaV could not protect subsequent 
disease caused by different genogroups or genotypes of SaV. Hyper-immune sera and 
monoclonal antibodies raised against virus like particle (VLP) have showed the distinct 
antigenicity among different genogroups and genotypes of SaV(61, 68, 74). Our finding 
together with distinct the antigenicity among SaV genotypes and genogroups suggested 
that children may develop genogroup/genotype-specific immunity and this observation 
will need to be taken into account in development of vaccines, which may need to 
include multiple genotypes to achieve clinical protection.  
    I found multiple genogroups and genotypes were circulating at the same time in 
shantytown of Lima and no certain genogroup or genotype was predominant during the 
study period. This pattern differed from norovirus, in which genogroup II or genotype 
II.4 have been predominant for decades worldwide (75). Some uncommon genotypes of 
SaV like GI.6, GI.7 and GII.5 were observed in this study. The emerging genotypes 
GI.2 (n=2) and GIV (n=2), which caused outbreaks at global level during this study 
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period (5, 36) were also detected, but not dominant in this community. According to 
Oka T classification (11, 14), one novel genotype could be designated if one group of 
strains display more than 0.169 pairwise distance of entire VP1 sequence with known 
genotypes. I sequenced one of full VP1 region of five novel strains in GII, which shared 
99% nucleotide similarity at partial VP 1 region, and found that it displayed 0.298–
0.466 pairwise distance with other known genotypes in GII, therefore could represent 
one novel genotype. These five strains were detected between 2008 and 2009 and 
showed 99% similarity at partial capsid region with one reference strain (HM590581) 
from one outbreak in USA in 2010 (unpublished data).  
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V. Conclusion 
1. Study 1 
    This is the first study investigating the prevalence and genetic characteristics of 
SaV in the Philippines. SaV was constantly detected in a high proportion of hospitalized 
children with acute gastroenteritis during the study period. I identified a novel, naturally 
occurring recombinant, SaV GII.1/GII.4, in three cases from two different islands in the 
Philippines. A continuous monitoring is imperative to define the significance of the 
novel recombinant strain. 
2. Study 2 
    This study showed SaV leaded to acute gastroenteritis in children less than two 
years old. The SaV AF in diarrhea was higher in the second year than the first year life 
of infants. Ten genotypes were circulating from June 2007 to May 2010 in the 
shantytown in Lima and one novel genotype in GII was found. Symptomatic reinfection 
with different genogroups and genotypes in eight children suggested children may 
develop genotype-specific immunity. This study broadened the knowledge of 
pathogenicity, genetic diversity, and protective immunity of SaV in human. 
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VII. Figures 
 
Figure 1. The virion of SaV 
The picture was provided from Swiss Institute of Bioinformatics. SaV is 
non-enveloped, capsid of about 27–40 nm in diameter, with T=3 icosahedral 
symmetry. The capsid is composed of 180 capsid proteins. The virion RNA is 
infectious and serves as both the genome and viral messenger RNA. 
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Figure 2. Diagram of sapovirus genomic organization based on the GII 
Bristol/98/UK strain (GenBank accession no. AJ249939).  
A schematic diagram of the sapovirus genomic organization, including 5’NTR, 
3’NTR, two common open reading frames (ORF1 and ORF2) and the predicted 
viral nonstructural proteins (NS1 [p11], NS2 [p28], NS3 [NTPase], NS4 [p32], 
NS5 [VPg], and NS6-NS7 [protease–RNA-dependent RNA polymerase 
{RdRp}]), and structural proteins VP1 and VP2 are shown.  
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Figure 3. Location of three study hospitals in the Philippines. The hospitals were 
marked by blue H and the islands where hospitals were located were shaded in gray 
color. Eastern Visayas Regional Medical Center (EVRMC) is located in Leyte Island; 
Ospital ng Palawan (ONP) and Philippine Children's Medical Center (PCMC) are 
located in Palawan Island and Metro Manila, respectively.  
 
 
 
 
Figure 4. Schematic diagram of the full genome amplification of TGO12-028. 
TGO12-028 was amplified in four overlapped segments. The primers were named 
according to their respective nucleotide position of Bristol/98/UK (AJ249939). 
14 nt 6856 nt
7350 nt
5’ NTR
3 ′ NTR
NS1 NS3NS2 NS4 NS5 NS6 Capsid
ORF1
ORF2
5174 nt
polymerase
401F
5074F
5177R
2709F
2922R
TX30SXN
PCR  
amplicons 
600R
1F
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Figure 5. The detection of sapovirus by different age groups among hospitalized 
children aged less than 5 years with acute gastroenteritis in the Philippines. The 
y-axis indicated the No. of tested cases. The total No. of children was divided into five 
age groups as shown in x-axis. The black bars and grey bars indicated the SaV-positive 
and negative cases, respectively. The numbers above bars showed the positive cases and 
percentage (in parenthesis). 
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Figure 6. Phylogenetic analysis of the sapovirus capsid gene (364 nt, a) and the 
polymerase gene (463 nt, b) in the Philippines. The phylogenetic tree was inferred 
using the neighbor-joining method (Kimura 2-parameter model) using MEGA5. The 
tree was drawn to scale, with branch lengths in the units of the number of base 
substitutions per site. The bootstrap value (≥80%) is shown next to the branches. Strains 
from EVRMC, ONP, and PCMC are marked with ♦, ▲, and ●, respectively. The 
recombinant strains are represented by thick branches in both trees. 
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Figure 7. TGO12-028 was plotted against the full genome sequence of 
Bristol/98/UK and the 3′ terminal of the available genome sequence (4523–7460 nt) 
of GII.4 Kumamoto6/Mar2003/JPN. The x-axis indicates the nucleotide position of 
TGO12-028 and the y-axis shows the similarity between the query strain and reference 
strains. The vertical dotted line indicates the recombination breakpoint. 
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Figure 8. Prevalence of SaV in diarrheal and non-diarrheal stool samples by age in 
the nested case control study in Peru.  
The y-axis indicated the percentage of SaV in stools. The x-axis showed age groups of 
infants with stools. The black bars and grey bars indicated diarrheal and non-diarrheal 
stools. 
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Figure 9. Phylogenetic analysis of the sapovirus capsid gene(628nt) in nested case 
control study in Peru.The phylogenetic tree was inferred using the neighbor-joining 
method (Kimura 2-parameter model) using MEGA5. The tree was drawn to scale, with 
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branch lengths in the units of the number of base substitutions per site. Reference 
strains are marked with ▲. 
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Figure 10. Phylogenetic analysis of the full sapovirus capsid gene in nested case 
control study in Peru.The phylogenetic tree was inferred using the neighbor-joining 
method (Kimura 2-parameter model) using MEGA5. The tree was drawn to scale, with 
branch lengths in the units of the number of base substitutions per site. The novel strain 
obtained in this study are marked with ▲ 
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VIII. Tables 
Table 1. Primers used for SaV in study 1. 
Usage Primer/Probe Nucleotide Sequence (5’–3’) Position Source  
Real-time PCR 
Sav 1F TTGGCCCTCGCCACCTAC 5077–5094 a 
(26) 
Sav 5F TTTGAACAAGCTGTGGCATGCTAC 5112–5135 a 
Sav124 F GAYCASGCTCTCGCYACCTAC 5074–5094 a 
Sav1245 R CCCTCCATYTCAAACACTA 5159–5177 a 
Sav124 probe VIC-CCRCCTATRAACCA-MGB 5101–5117 a 
Sav5 probe VIC-TGCCACCAATGTACCA-MGB 5142–5157b 
Genotyping of 
capsid 
SV-F13 GAYYWGGCYCTCGCYACCTAC 5074–5094a 
 
(25) 
SV-F14 GAACAAGCTGTGGCATGCTAC 5074–5094a 
SV-R13 GGTGANAYNCCATTKTCCAT 5876–5861a 
SV-R14 GGTGAGMMYCCATTCTCCAT 5876–5861a 
SV F22 SMWAWTAGTGTTTGARATG 5154–5172 a 
SV R2 GWGGGRTCAACMCCWGGTGG 5591–5572a 
Genotyping of 
polymerase 
SaV4579a CCATCTGGGATGCCATTYAC 4525–4544a Current 
study 
SaV4579b CCNTCDGGNATGCCNTTYAC 4525–4544a 
SaV1245R CCCTCCATYTCAAACACTA 5159–5177 a (26) 
(26) Amplification/ 
sequencing of full 
TX30SXN GACTAGTTCTAGATCGCGAGCGGCCGCCCT 29 Oligo dT 
Current 
study 
1F GTGATTGGTTRGTATGGCTTC 1–21 c 
600R TTTACCACYTGTCGCCACAT 581–600 c 
401F TACTCCACCGATTCGCTC 401–418c 
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genome 2922R CGCCACTCATCRTACTC 2906–2922 c 
2709F ATCACCCGCAACATGAC 2693–2709 c 
2099R TAGCWGCCATGTAKGATTTC 2080–2099 c 
3491F GCATCATYAATGGTTACCC 3489–3507 c 
4292R ACCTGGCAACTRTCCATGTT 4292–4311 c 
5744F CARCCVYTNATCAACCCSTT 5750–5769 c 
6650F ATGGCAGTGTTCAATGTGGA 6650–6669 c 
aPosition in complete sapovirus GI genogroup sequence (Manchester, X86560) 
bPosition in complete genome of sapovirus GV genogroup 
(NongKhai-24/Thailand, AY646856) 
cPosition in complete genome of GII genogroup (Bristol/98/UK, AJ249939) 
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Table 2. Demographic information, genotype, viral load, and viral infection of 29 
SaV-positive cases in the study 1. 
Sample ID 
Sex 
(M/F) 
Age 
( _y_m) 
Vaccination 
of rotavirus 
Genotype Hospital 
Viral load 
(cDNA/µl) 
Sole/ 
Co-infection 
TGP12-019 F 1y3m No GII.1 PCMC 1731656  sole 
TGO13-057 M 0y10m No GII.1 ONP 256  norovirus 
TGE13-075 M 0y10m Unknown Unknown EVRMC 296  sole 
TGO12-028 F 0y11m No GII.1/II.4 ONP 1367406  sole 
TGE13-016 M 0y4m No GII.1 EVRMC 12664  sole 
TGP12-024 F 0y5m No GI.1 PCMC 15479025  sole 
TGE13-103 M 0y5m No GII.1 EVRMC 1125336  rotavirus 
TGO13-108 F 0y6m Unknown GII.1 ONP 15942782  rotavirus 
TGO13-081 F 0y7m No GII.1 ONP 123682  sole 
TGE12-100 M 0y7m No GII.1 EVRMC 1408  sole 
TGP12-021 F 0y8m No GII.1 PCMC 232630507  astrovirus 
TGE12-081 M 0y9m No GI.1 EVRMC 10734  sole 
TGE13-057 F 0y9m No GI.1 EVRMC 1073  sole 
TGO12-040 F 1y0m No GI.1 ONP 623551  sole 
TGE12-094 M 1y11m No GII.1 EVRMC 5640  sole 
TGE12-097 M 1y2m No GV EVRMC 1125  rotavirus 
TGE12-084 F 1y3m No GV EVRMC 2031  sole 
TGE13-058 M 1y4m No GII.1 EVRMC 15029  rotavirus 
TGE12-009 M 1y5m No GII.1/II4 EVRMC 519  rotavirus 
TGE13-033 M 1y6m No Unknown EVRMC 443  rotavirus 
TGE13-167 F 1y7m No GI.2 EVRMC 464159  sole 
TGO13-115 M 1y8m Unknown GI.1 ONP 2728  astrovirus 
TGE12-047 M 1y9m No GI.1 EVRMC 5223  sole 
TGO12-013 M 2y0m No GI.1 ONP 685  sole 
TGE13-109 F 2y0m No Unknown EVRMC 627  norovirus 
TGE12-087 M 2y3m No GII.1 EVRMC 1594  sole 
TGE13-148 M 3y9m No GI.2 EVRMC 27607  sole 
TGE12-030 F 4y7m No GII.1/II.4 EVRMC 74438  sole 
TGO13-083 F 4y9m No GII.1 ONP 366524  sole 
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Table 3. The age and season distribution of 300 diarrheal stools which were 
proportionally selected from diarrhea episodes (in parenthesis) in the birth cohort 
study in Peru. 
Age group 
(months) 
Season 
Total 
Dec-Feb Mar-May Jun-Aug Sep-Nov 
0–2 4(10) 6(19) 10(28) 6(17) 26(74) 
3–5 7(19) 8(24) 12(35) 15(42) 42(120) 
6–8 12(34) 7(21) 14(40) 11(31) 44(126) 
9–11 13(38) 13(38) 5(14) 11(32) 42(122) 
12–14 13(38) 10(30) 13(38) 4(12) 40(118) 
15–17 8(24) 11(32) 10(28) 12(35) 41(119) 
18–20 11(30) 5(13) 12(33) 7(21) 35(97) 
21–23 9(26) 9(26) 5(13) 7(21) 30(86) 
Total 77(219) 69(203) 81(229) 73(211) 300(862) 
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Table 4. Primers and sequences used in this study 2. 
aPosition in complete sapovirus GI genogroup sequence (Manchester, X86560) 
bPosition in complete genome of sapovirus GV genogroup (NongKhai-24/Thailand, 
AY646856) 
cPosition in complete genome of GII genogroup (Bristol/98/UK, AJ249939) 
Usage Primer/Probe Nucleotide Sequence (5’–3’) Position Source  
Real-time PCR 
Sav 1F TTGGCCCTCGCCACCTAC 5077–5094 a 
(26) 
Sav 5F TTTGAACAAGCTGTGGCATGCTAC 5112–5135 a 
Sav124 F GAYCASGCTCTCGCYACCTAC 5074–5094 a 
Sav1245 R CCCTCCATYTCAAACACTA 5159–5177 a 
Sav124 probe VIC-CCRCCTATRAACCA-MGB 5101–5117 a 
Sav5 probe VIC-TGCCACCAATGTACCA-MGB 5142–5157b 
Genotyping  
SV-F13 GAYYWGGCYCTCGCYACCTAC 5074–5094a 
 
(25) 
SV-F14 GAACAAGCTGTGGCATGCTAC 5074–5094a 
SaVF1245 TAGTGTTTGARATGGAGGG 5159–5177 a 
SaV5857R-1 CWGGDGANAYHCCATTBTCCAT 5857-5878 a 
SaV5857R-2 GGNGANMNNCCRTTNTSCAT 5857-5876 a 
Amplification of 
VP1 
 
SV-F13 GAYYWGGCYCTCGCYACCTAC 5074–5094a 
Current study SV-F14 GAACAAGCTGTGGCATGCTAC 5074–5094a 
SaVGIIR GCTCCWGTRAACCAAGACATTATTC 6851-6875 c 
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Table 5. The symptoms of 37 SaV-positive cases in nested case-control study in 
Peru 
Level of symptom  n % 
  37  
Duration of episodes  <2 days 7 18.9 
 2-3 days 16 43.2 
 ≥4 days 14 37.8 
Maximum number of diarrhea stool per day 3 9 24.3 
 4-5 19 51.4 
 ≥6 9 24.3 
Duration of vomiting  No 22 59.5 
 1-2 days 13 35.1 
 ≥3 days 2 5.4 
Fever yes 4 10.8 
 no 34 91.9 
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Table 6. Demographic information, viral load, genotype and repeated infection of 
54 SaV-positive stool samples. 
Infant 
ID 
Sample 
ID 
Sampling 
date 
Age 
(Month) 
Diarrhea  
or not 
Viral load 
(cDNA/µl) 
Genotype  
Repeated 
infection 
PX001 330 10/5/08 18 Diarrhea 351685  GII.new 
 
PX011 268 3/12/09 23 Diarrhea 1459  GI.1 
 
PX016 42 9/23/07 5 Non-diarrhea 2067  GII.4 
 
PX024 521 4/24/08 13 Non-diarrhea 5132  GII.new 
 
PX028 312 1/9/09 20 Diarrhea 422319  GI.7 
 
PX033 540 5/12/08 11 Diarrhea 2542  GIV 
 
PX039 283 12/5/08 18 Diarrhea 4953040  GI.1 
 
PX046 
 
582 7/13/08 13 Diarrhea 44274518  GI.6 1st infection 
273 11/16/08 17 Diarrhea 61988010  GI.1 2nd infection 
PX049 520 4/20/08 11 Diarrhea 16324  GI.2 
 
PX067 192 4/20/09 22 Non-diarrhea 3455  GI.2 
 
PX074 425 8/26/08 13 Non-diarrhea 23679  GII.new 
 
PX080 
 
421 8/25/08 12 Diarrhea 1762600  GIV 1st infection 
230 5/25/09 21 Diarrhea 2192934  GII.2 2nd infection 
PX096 296 12/15/08 16 Non-diarrhea 31810032  GV 
 
PX115 412 8/11/08 11 Non-diarrhea 440139  GV 
 
PX117 538 5/7/08 8 Diarrhea 294599  GI.7 
 
PX119 335 10/9/08 13 Diarrhea 4533256  GI.2 
 
PX133 313 1/9/09 16 Diarrhea 16812838  GI.1 
 
PX135 
 
505 3/17/08 6 Diarrhea 878  GIV 1st infection 
78 6/19/09 21 Diarrhea 47806525  GV 2nd infection 
PX136 518 4/21/08 7 Non-diarrhea 624  GI.6 
 
PX139 95 7/15/09 21 Diarrhea 2928645  GII.1 
 
PX143 201 4/21/09 18 Non-diarrhea 199526  GII.2 
 
PX147 406 7/30/08 10 Diarrhea 370878  GII.4 
 
PX147 426 8/24/08 11 Non-diarrhea 1548  GII.4 
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PX152 
 
321 1/19/09 16 Diarrhea 78038  GI.6 1st infection 
250 2/10/09 16 Diarrhea 3888  GI.7 2nd infection 
PX159 
 
572 6/19/08 9 Diarrhea 44274518  GII.4 1st infection 
322 1/27/09 16 Diarrhea 56400383  GI.1 2nd infection 
PX160 526 4/28/08 7 Diarrhea 2031  untypable 
 
PX164 70 6/1/09 20 Non-diarrhea 702  GI.1 
 
PX177 195 4/20/09 17 Diarrhea 112534  GII.5 
 
PX180 570 6/17/08 9 Diarrhea 780  untypable 
 
PX188 415 8/12/08 7 Non-diarrhea 115905  GII.1 
 
PX190 535 5/7/08 4 Non-diarrhea 228546  GI.7 
 
PX196 142 10/27/09 21 Non-diarrhea 291140  GV 
 
PX198 
 
545 5/12/08 4 Non-diarrhea 534817  GII.1 1st infection 
157 12/15/09 23 Diarrhea 5132  GII.2 2nd infection 
PX212 
 
191 4/20/09 15 Diarrhea 8229712  GI.1 1st infection 
143 10/30/09 21 Diarrhea 440139  GII.new 2nd infection 
PX216 141 10/27/09 20 Diarrhea 8576959  GV 
 
PX220 272 3/16/09 14 Diarrhea 364367  GI.7 
 
PX245 588 2/22/10 23 Diarrhea 272833  GI.1 
 
PX250 266 3/10/09 12 Diarrhea 174191  GI.7 
 
PX262 221 5/13/09 13 Diarrhea 4273  untypable 
 
PX267 207 4/27/09 12 Diarrhea 3088471  GII.2 
 
PX268 206 4/27/09 13 Diarrhea 3181  GV 
 
PX269 171 3/4/10 23 Diarrhea 631  untypable 
 
PX282 176 4/13/10 20 Non-diarrhea 12151  GI.7 
 
PX286 220 5/11/09 8 Non-diarrhea 18920  GII.new 
 
PX287 
 
79 6/18/09 8 Diarrhea 141671  GIV 1st infection 
137 10/12/09 11 Diarrhea 6162311  GI.1 2nd infection 
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